The Saudi sovereign fund’s focus on UnitedHealth and Lilly calls, alongside new positions in Pinduoduo, indicates a shift away from Lilly’s core pharma exposure. With patent cliffs looming for non-GLP-1 drugs by 2028 and high valuations, Lilly faces risks of a 10% pullback, particularly if regulatory scrutiny on drug pricing intensifies.
Microsoft’s latest quarterly results reveal a worrisome trend ...
Buying NVIDIA is as straightforward as sending...
Sharps’ $400 million treasury commitment is significant, but warrant exercises could dilute SOL’s value by 5-10%. With hype-driven rallies often fading (e.g., 2022’s 30% post-pump drop), Solana faces volatility risks if adoption stalls, suggesting investors wait for confirmation of sustained dApp growth before entering.
Buying NVIDIA is as straightforward as sending...
Microsoft’s latest quarterly results reveal a worrisome trend ...
Sharps’ $400 million treasury commitment is significant, but warrant exercises could dilute SOL’s value by 5-10%. With hype-driven rallies often fading (e.g., 2022’s 30% post-pump drop), Solana faces volatility risks if adoption stalls, suggesting investors wait for confirmation of sustained dApp growth before entering.
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
testtest news
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Massive AI Expansion Across Creative Cloud Massive AI Expansion Across Creative Cloud
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Amazon is a top pick for a decade-long hold
